论文部分内容阅读
目的观察卡培他滨联合顺铂方案(XP)治疗晚期头颈部鳞癌的疗效及不良反应,并与5-氟尿嘧啶联合顺铂方案(FP)作随机对照。方法 XP组35例患者:卡培他滨,2500mg/(㎡.d),分两次口服,餐后30min,第1～14d,顺铂20 mg/㎡,静脉滴注,第1～4d。FP组37例患者:5-FU 750mg/(㎡·d),CIV9,6h,第1～4d,顺铂20 mg/㎡,静脉滴注,第1～4d。以上方案均为21天重复。结果 XP组和FP组的有效率为57.1%和54.1%(P>0.05);中位OS为16.5和15.8月(P>0.05)。XP组III-IV度粒细胞减少,恶心呕吐,腹泻和口腔炎发生率明显低于FP组。结论 XP和FP均为治疗晚期头颈部鳞癌的较好的化疗方案,XP方案毒副作用小,治疗耐受性好。
Objective To observe the curative effect and side effects of capecitabine combined with cisplatin (XP) in the treatment of advanced head and neck squamous cell carcinoma (SCC). Randomized controlled trials were conducted with 5-fluorouracil combined with cisplatin (FP). Methods 35 patients in XP group received capecitabine 2500 mg / (㎡.d) orally twice daily for 30 min, 1 to 14 d, and 20 mg / m2 cisplatin intravenously for 1 to 4 days. FP group 37 patients: 5-FU 750mg / (㎡ · d), CIV9, 6h, 1 ~ 4d, cisplatin 20 mg / ㎡, intravenous drip, 1 ~ 4d. The above programs are 21 days repeat. Results The effective rates of XP group and FP group were 57.1% and 54.1%, respectively (P> 0.05). The median OS was 16.5 and 15.8 months (P> 0.05). The incidence of neutropenia, nausea and vomiting, diarrhea and stomatitis in group III-IV of XP group was significantly lower than that in FP group. Conclusions Both XP and FP are better chemotherapy regimens for advanced head and neck squamous cell carcinoma. The XP regimen has small side effects and good therapeutic tolerance.